BLOG
La taxe de 1% sur l’innovation continuera d’être payée par les PME. Comment corriger l’erreur ?
Une victoire de la gauche basée sur le mépris des PME et des start-ups qui investissent dans l’innovation et leur croissance
Pourquoi taxer l’innovation et la croissance à 1% ?
Le 13 février nous votons sur la suppression du droit de timbre sur l’émission de capital propre.
Quand aurons-NOUS un vaccin contre les variants COVID-19 ?
Après une promesse en juin par le CEO de Pfizer à la conférence du G7, il y a enfin des nouvelles avec des essais cliniques en cours et un article dans la revue scientifique Nature.
Discussion hallucinante avec un couple sceptique sur le COVID
Après plusieurs posts sur le COVID, je ne résiste pas à relater une discussion surréaliste dans le tram avec un jeune couple ne portant pas le masque.
Les messages fallacieux des radios US et des antis loi COVID
Certains podcasts et radios américaines produisent des émissions scientifiquement trompeuses sur le Covid. Les opposants de la loi Covid aussi.
NEWS
Mablink Bioscience appoints Pejvack Motlagh, M.D., as Chief Medical Officer
Mablink appoints Pejvack Motlagh, M.D., as CMO who will serve on the Executive Management Team and report directly to Mablink’s CEO.
TheraPPI to present at Event BioValley Basel – Business Angel Chapter
TheraPPI’s CEO will present at BioValley Basel on 19 June 2023.
TheraPPI to present at TechTour in Paris
TheraPPI’s CEO will present at TechTour in Paris on 2nd June 2023.
TheraPPI among the Finalists of the 2023 >>venture>>
TheraPPI Bioscience is finalist of 2023 >>venture>>, a highly competite startup challenge.
NETRIS Pharma Doses First Patient in Pancreatic Cancer Clinical Study with NP137
NETRIS Pharma initiates Lap-NET1, a multicenter, prospective, single arm, proof-of-concept trial of NP137, in combination with mFOLFIRINOX in first line patients with locally advanced pancreatic ductal adenocarcinoma.
Mablink Bioscience to Present Promising Preclinical Data for Lead ADC Candidate MBK-103 at the AACR
Mablink will present preclinical efficacy and safety data on its lead program, MBK-103, at the AACR Meeting 2023 on April 17, 2023, in Orlando, Florida.
NETRIS Pharma Doses First Patient in Hepatocellular Carcinoma (HCC) Clinical Study with NP137
NETRIS Pharma initiates Liver-NET1, a multicenter, prospective, single arm, proof-of-concept trial of NP137, in combination with atezolizumab-bevacizumab in first line patients with advanced hepatocellular carcinoma.
A new review on the history and future of ADC payloads published by Mablink’s scientists
Mablink announces the publication of a review article on payload and ADC in Journal of Hematology & Oncology.
NETRIS Pharma led consortium awarded €1.2 million Eurostar grant to explore netrin-1 targeted therapeutics
A consortium of leading European academic institutions and biotech companies have been awarded a €1.2 million Eurostar grant for ACTaNet project to generate preclinical PoC data with NETRIS’s NP137 for treating arthritis and metastatic bone cancer related chronic pain.
France 2030: Mablink is awarded 1.8 million euros in the i-Nov innovation competition
Mablink is the winner of the 9th wave of the i-Nov innovation competition organized by Bpifrance and receives a grant of 1.8 million euros.
NETRIS Pharma Doses First Patient in Phase 2 Study of NP137 for Checkpoint Inhibitor Resistance
NETRIS Pharma initiates the Phase 2 ImmunoNET trial to test NP137, as add- on therapy for immunotherapy resistance.
€31 million Series A funding round led by Sofinnova Partners and Mérieux Equity Partners
Mablink has raised a €31 million Series A funding round led by Sofinnova Partners and Mérieux Equity Partners, with participation from the existing investors.